Sunil Asnani, MD
Endocrinology, Diabetes & Metabolism · Brick, NJNPI 1669574281
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $95,259 of the $104,403 with a category attached, or 91.2%. Novo Nordisk accounts for 98.2% of it on its own, with 16 other manufacturers making up the rest. Among endocrinology, diabetes & metabolism clinicians in NJ with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 177 payments — averaging $589.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$103K
- AstraZeneca$664
- Senseonics, Incorporated$473
- Abbott$316
- Insulet Corporation$113
- Boehringer Ingelheim$84
- plus $237 from 11 others
Across 78 payments — averaging $2687.81 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AbbVie$210K
What the payments were for
- Speaking & faculty fees$95,25991%
- Travel & lodging$5,4725%
- Food & beverage$3,5473%
- Education$150%
- Other$1100%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 114 | $102,515 |
| AstraZeneca | 18 | $664 |
| Senseonics, Incorporated | 6 | $473 |
| Abbott | 5 | $316 |
| Insulet Corporation | 11 | $113 |
| Boehringer Ingelheim | 6 | $84 |
| Sanofi-aventis U.S. LLC | 4 | $53 |
| Lilly USA, LLC | 3 | $44 |
| Valeritas, Inc. | 2 | $32 |
| Nevro Corp. | 1 | $21 |
| Corcept Therapeutics | 1 | $14 |
| Mannkind Corporation | 1 | $14 |
| Amneal Pharmaceuticals LLC | 1 | $14 |
| Medtronic | 1 | $13 |
| Johnson & Johnson | 1 | $13 |
| Merck | 1 | $13 |
| Clarus Therapeutics Inc. | 1 | $6 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- RYBELSUS$49,620
- Ozempic$35,167
- Tresiba$8,411
- Xultophy 100/3.6$3,293
- Eversense$400
- FARXIGA$232
- FreeStyle Libre 2$157
- LOKELMA$111
- PRECISION XTRA$110
How this compares
$104,403 in reported general payments places this provider in the 95th percentile of 367 endocrinology, diabetes & metabolism providers in New Jersey.
See all endocrinology, diabetes & metabolism providers in New Jersey →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 281 | $497,517 |
| JardianceEmpagliflozin | 194 | $246,323 |
| TrulicityDulaglutide | 106 | $183,852 |
| FarxigaDapagliflozin Propanediol | 113 | $141,635 |
| MounjaroTirzepatide | 69 | $111,042 |
| RybelsusSemaglutide | 74 | $99,548 |
| Tresiba Flextouch U-200Insulin Degludec | 59 | $78,088 |
| JanuviaSitagliptin Phosphate | 39 | $51,149 |
| Humalog Kwikpen U-100Insulin Lispro | 129 | $46,111 |
| Tresiba Flextouch U-100Insulin Degludec | 86 | $43,239 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 53 | $30,421 |
| SynjardyEmpagliflozin/Metformin Hcl | 27 | $30,325 |
| Omnipod Dash Pods (Gen 4)Insulin Pump Cart,cont Inf,bt | 16 | $30,195 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 15 | $29,923 |
| InvokanaCanagliflozin | 25 | $29,625 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus, Novolog | $102,515 | $605,557378 claims |
| Boehringer IngelheimJardiance, Synjardy, Synjardy Xr, Tradjenta, Glyxambi | $84 | $342,786290 claims |
| Lilly USA, LLCTrulicity, Mounjaro, Humalog | $44 | $302,845195 claims |
| AstraZenecaFarxiga | $664 | $141,635113 claims |
| MerckJanuvia, Janumet | $13 | $74,46464 claims |
| Johnson & JohnsonInvokana | $13 | $29,62525 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $53 | $20,84512 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $14 | $9,798824 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 367 endocrinology, diabetes & metabolism providers in New Jersey.
Other endocrinology, diabetes & metabolism in Brick
- Barry GertzRahway$903K
- Nawras MakhsidaRandolph$882K
- Marc SandbergFlemington$567K
- Joanne WaldstreicherNew Brunswick$441K
- Gregory BaroneCherry Hill$433K
- Navtika DesaiHillsborough$408K
- Taher ModarressiPennington$402K
- Atara SchultzTeaneck$357K
- Anthony CannonTurnersville$296K
- Stanislav GoykhmanLyndhurst$278K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.